Therapy comparison for multiple sclerosis
Long-term effect of a newly developed drug compared with teriflunomide.
Description
In this project, the longterm effectiveness (i.e. EDSS progression) of a only clinically tested new drug was compared to Teriflunomide. For this purpose, in a first step, the two data sets (Randomized Clinical Trial Data of the new drug and observational Data for Teriflunomide) were processed for comparability using statistical tools such as Propensity Score Matching. For the effectiveness, Cox regression and various sensitivity analyses were applied.
Key Data
Projectlead
Deputy Projectlead
Project status
completed, 09/2020 - 02/2021
Funding partner
Third party
Publications
-
Is there an impact of early initiation of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis in the German registry?
2022 Braune, Stefan; Drewek, Anna; Bergmann, Arnfin; Schuler, Maximilian; Ait-Tihyaty, Maria; H Le, Hoa; Keenan, Alex; Gandhi, Kavita; van Denderen, Jacqueline
-
Assessing the impact of persistency for disease-modifying therapies in a German registry for multiple sclerosis
2022 Braune, Stefan; Drewek, Anna; Bergmann, Arnfin; Keenan, Alex; Gandhi, Kavita; Schuler, Maximilian; van Denderen, Jacqueline; Ait-Tihyaty, Maria; H Le, Hoa